antifungal/nausea

TECHNICAL FIELD The present invention relates to the field of therapeutic uses for erythropoietin, and more particularly, to treating subjects with a recombinant erythropoietin prepared from an Apa I human genomic DNA fragment, including recombinant erythropoietin expressed in transformed baby

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is relevant to the field of suppressing sensory afferent neuron mediated symptoms and the manufacture of agents and compositions which suppress the same. 2. Discussion of the Related Art. Sensory afferent nerves mediate a

BACKGROUND Nausea associated symptoms can severely disrupt daily normal activity. In modern societies, a hectic lifestyle is common. Dealing with a disruption in that lifestyle may lower quality of life and may induce many other ailments such as for example, anxiety and stress. In addition, nausea

BACKGROUND OF INVENTION 1. Field of the Invention The present invention relates to a novel method of administering anti nausea and anti emetic agents and to novel dosage forms containing such agents adapted for nasal administration. The invention provides a novel method of administering therapeutic

This invention relates to a new medical use for a group of heterocyclic compounds and pharmaceutical compositions containing them. In particular it relates to certain tetrahydrocarbazolone derivatives which may be used to promote gastric emptying and as anti-emetic agents. A particularly important

FIELD OF THE INVENTION The present invention relates to sulfonamide derivatives, to the process for preparing them and to their therapeutic use. BACKGROUND OF THE INVENTION Orexins A and B (or hypocretins 1 and 2) are hypothalamus neuropeptides of 33 and 28 amino acids, respectively, recently

The present invention relates to the novel compound 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoro pyrimidine, its preparation and its therapeutic use, its physiologically acceptable salts, the processes for their preparation and their application as medicaments in human

SUMMARY OF THE INVENTION According to our invention, in its broadest aspect, we provide a compound corresponding to the general formula (I): ##STR1## in which: R is a lower (C.sub.1 -C.sub.6) alkoxy or alkenoxy; R.sub.1 and R.sub.2, which may be the same or different, are selected from hydrogen,

Propofol (2,6-diisopropylphenol) is an intravenous sedative/hypnotic agent used extensively for induction and maintenance of general anesthesia, sedation of critically ill patients and procedural sedation (e.g., endoscopy). See Langly, M. S. and Heel, R. C. Drugs, 1988, 35, 334-372. Propofol is only

FIELD OF THE INVENTION This invention relates to new therapeutic uses of tramadol and its structural and/or functional analogues, and to new formulations thereof. BACKGROUND OF THE INVENTION Tramadol has the chemical name (+/-)-trans (RR,SS)-2-[(di-methylamino)methyl]-1-(3-methoxyphenyl)

CROSS-REFERENCE TO RELATED APPLICATIONS Not applicable. STATEMENT REGARDING FEDERALLY SPONSERED RESEARCH OR DEVELOPMENT Not applicable. REFERENCE TO A MICROFICHE APPENDIX Not applicable. BACKGROUND OF THE INVENTION 1. Field of the Invention A new use for estrone, derivatives of estrone, equilin and

FIELD OF THE INVENTION The invention relates to methods of treating mammals, for example humans, to reduce the occurrence of undesired administration reactions, to treat an LFA-1 mediated disease, to condition a mammal to tolerate high doses of a therapeutic compound and to down modulate a cell

FIELD OF THE INVENTION The invention relates to methods of treating mammals, for example humans, to reduce the occurrence of undesired administration reactions, to treat an LFA-1 mediated disease, to condition a mammal to tolerate high doses of a therapeutic compound and to down modulate a cell

FIELD OF THE INVENTION The invention relates to methods of treating mammals, for example humans, to reduce the occurrence of undesired administration reactions, to treat an LFA-1 mediated disease, to condition a mammal to tolerate high doses of a therapeutic compound and to down modulate a cell

DESCRIPTION BACKGROUND OF THE INVENTION 1. Field of the Invention The invention is generally related to the therapeutic use of .DELTA..sup.9 Tetrahydrocannabinol (.DELTA..sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of .DELTA..sup.9